secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264690
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced
--------------------------------------------------------------------------------

- Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.
- Delivered 4,388 clinical tests, +26% sequential and +364% YoY; submitted third Medicare dossier for lung cancer.
- FY 2025 revenue guidance narrowed to $68-73M (from $70-80M); clinical tests reimbursed cut to $1.5-2M from $3-6M.
- Cash, cash equivalents and investments $150.5M; cash used in operations and capex $23.4M in Q3.
- Q4 2025 revenue outlook $15.7-20.7M; pharma/services revenue $12-17M; population sequencing ~$3.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525264690/0001193125-25-264690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525264690/psnl-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer